213 results about "Injections subcutaneous" patented technology

A needle tip protective device for use with percutaneous entry needles. In one embodiment, the needle tip protective device includes a needle guard slidably mounted on a hypodermic needle, the latter having a needle tip located at the distal end thereof, and a change of profile formed medially there along. The needle guard is movable along the hypodermic needle and engageable with the change in profile formed thereon. The engagement with the change in profile is configured to correspond with the ability of the needle trap to entrap the needle tip once the needle trap has advanced the sufficient distance distally along the hypodermic needle. In further refinements, the needle trap may be biased toward the distal needle tip of the needle.

An automatic injection and retraction device having a longitudinal axis is provided that includes an injection assembly, a retraction assembly, and a pre-filled syringe cartridge. The injection assembly has an activation-prevention feature moveable between an on position and an off position. The retraction assembly has a needle guard that is removable in a direction along the longitudinal axis upon application of a removal force. The pre-filled syringe cartridge has a hypodermic needle with a needle sheath thereon. The retraction and injection assemblies are secured to one another so that the pre-filled syringe cartridge is in the retraction assembly with the needle sheath secured to the needle guard. The retraction and injection assemblies are configured so that, upon application of a twisting torque to the injection and retraction assemblies, the activation-prevention feature moves from the on position to the off position simultaneous with applying the removal force to the needle guard.

A disposable double pointed injection needle has a needle hub to which a thin needle cannula is permanently fastened and which needle hub can be mounted on to a syringe comprising a dose setting and injection mechanism and a cartridge containing a liquid medicine to be injected subcutaneously into a human body. The needle hub is provided with a safety shield guided on the outside surface of the needle hub. The safety shield is urged in a direction away from the needle hub by a spring located between the needle hub and the safety shield. The safety shield has a number of protrusions guided in guiding tracks on the outside surface of the needle hub. The guiding tracks are designed such that the safety shield during injection is moved towards the needle hub, and after injection is moved away from the needle hub by the spring and locked in an irreversible position where the safety shield covers the needle cannula and prevents accidental needle stick injuries.

The delivery of a fluid cutaneously is effected by generating a suction force on a surface of a housing. A surface of a cutaneous layer is received under the suction force about which the proximal end of a needle thereby to pierce the cutaneous surface and to effect an injection of fluid. There is generated a suction force to operate the movement of a needle in the housing. The needle is moved under the suction force from the housing thereby to permit piercing a cutaneous layer. The bladder for containing fluid is emptied under the suction into the distal end of the needle and thereby permit the expulsion of fluid through the proximal end of the needle for injection below the cutaneous layer.

A cardiac event microrecorder comprising a hermetically sealed housing is shaped and dimensioned to facilitate the subcutaneous implantation of the microrecorder in a human patient by injection through the lumen of a hypodermic needle. The housing comprises a tubular central section of an electrically insulating material, the central section having spaced apart extremities. An electrically conductive sense electrode is secured to and seals each extremity. The housing may have an interior enclosing (1) electrical circuitry for processing, storing and telemetering data representing physiologic information detected by the sense electrodes; (2) a primary cell or rechargeable battery for electrically powering the electrical circuitry; and (3) an inductively couplable charger where a rechargeable battery is used. Also disclosed are a method of subcutaneously implanting a cardiac event recorder in a patient's thoracic region, and a handheld mapping device for determining an optimum location and orientation for the cardiac event microrecorder to be implanted.

An apparatus for subcutaneous administration of an injectable product, including a housing, a container for the product to be injected, an injection needle and a needle protection sleeve surrounding the injection needle, wherein the apparatus also includes an indicator to tell a user when the needle protection sleeve has attained its maximum distal position.

Apparatus and method for catheterized delivery or infusion of medication and anaesthesia are disclosed. The perforating catheter is first used to perforate the periodontal ligament and/or the cortical plate of bone tissue, and is then left in place and used as a catheter for insertion of a hypodermic needle of smaller gauge to deliver medication or anaesthesia to a target area. The perforator is a bevelled needle for drilling into the ligament or bone tissue. For drilling, the device comprises an adaptor which transmits the rotational movement from a dental hand piece or the like to the bevelled needle. A cap is also included for protecting the bevelled needle during storage of the device. The adaptor may have a rod which extends axially into the bevelled needle when the device is assembled for drilling. The rod is used to prevent the debris resulting from drilling from blocking the passage in the bevelled needle. As well, the rod reinforces the needle and maintains the alignment between the perforator and the adaptor for improved drilling efficiency. An adapter is disclosed which couples with the catheter once in place easing access to supply medication to difficult to reach areas.

A needle tip protective device for use with percutaneous entry needles. In one embodiment, the needle tip protective device includes a needle guard slidably mounted on a hypodermic needle, the latter having a needle tip located at the distal end thereof, and a change of profile formed medially there along. The needle guard is movable along the hypodermic needle and engageable with the change in profile formed thereon. The engagement with the change in profile is configured to correspond with the ability of the needle trap to entrap the needle tip once the needle trap has advanced the sufficient distance distally along the hypodermic needle. In further refinements, the needle trap may be biased toward the distal needle tip of the needle.

A needle tip protective device for use with percutaneous entry needles. In one embodiment, the needle tip protective device includes a needle guard slidably mounted on a hypodermic needle, the latter having a needle tip located at the distal end thereof, and a change of profile formed medially there along. The needle guard is movable along the hypodermic needle and engageable with the change in profile formed thereon. The engagement with the change in profile is configured to correspond with the ability of the needle trap to entrap the needle tip once the needle trap has advanced the sufficient distance distally along the hypodermic needle. In further refinements, the needle trap may be biased toward the distal needle tip of the needle.

A fluid delivery and extraction device enables the remote transfer of fluid to or from biological tissue. The device comprises an elongated member, a syringe movable relative to the elongated member and a pair of hypodermic needles movable relative to the elongated member. The elongated member has a distal portion which is adapted to be inserted into a biological structure. A steer wire or guide wire can be used to navigate the distal portion within cavernous biological structures, particularly body lumens. The distal portion has at least one retractable hypodermic needle that is configured to pierce the interior surface of a tubular biological structure and transfer fluid to or from the walls of the tubular biological structure. A physician can use a handle or other control mechanism provided at a proximal portion of the device to remotely move the hypodermic needles. A plunger can be used to transfer fluid through the hypodermic needles to or from the syringe. In operation, the hypodermic needles are deployed simultaneously or individually from the distal portion of the device. As the hypodermic needles move, they pierce the interior surface of the tubular biological structure. The hypodermic needles can also be configured to pass beyond the exterior surface of the tubular biological structure. The plunger is then used to transfer fluid either from the syringe to the patient or from the patient to the syringe. The hypodermic needles are then moved back to their retracted positions within the distal portion, and the device is withdrawn from the patient's body.

An apparatus for preventing blood exposure or contamination upon withdrawal of a hypodermic needle is provided. The apparatus may include a needle having a tip and a shield configured to at least partially entrap the needle tip upon withdrawal of the needle. The apparatus may further include a blood stabilizing material disposed such that upon withdrawal of the needle the blood stabilizing material is disposed in operative association with the needle tip such that blood carried by the needle is prevented from escaping the apparatus. In some exemplary implementations, the blood stabilizing material may be disposed on one or more surfaces of the shield. The shield of the hypodermic needle may include protective device and/or a housing for shielding the needle tip upon withdrawal. The housing may be adapted to at least partially cover the needle tip upon withdrawal of the needle. In some implementations, the housing may be adapted to allow the protective device to shield the needle before the needle is completely withdrawn.

The present invention provides compositions, methods, and kits for administration of nalmefene for treatment of alcoholism, nicotine dependence, or another condition for which treatment with nalmefene is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases nalmefene continuously with generally linear release kinetics for extended periods of time. Nalmefene is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with nalmefene.

The present invention relates to a medication delivery device comprising pump means and a reservoir adapted for containing a medicament. The pump means is adapted to transfer the medicament from the reservoir to an outlet arrangement, said outlet arrangement being adapted to be operatively connected to an associated hypodermic needle. The pumps means is adapted to deliver a set dose of medicament during one or more pump strokes, wherein the stroke volume(s) of said one or more pump strokes is variable. The present invention further relates to a method for adjusting stroke volumes to a set dose of medicament.

A steroid delivery system including a mixing syringe having a first chamber and a second chamber and at least one hypodermic needle is provided. The first chamber of the mixing syringe contains a pre-measured volume of a local anesthetic and the second chamber contains a pre-measured volume of a corticosteroid. An improved mixing syringe and a method for treating pain using the steroid delivery system of the present invention is also provided herein. The improved syringe achieves mixing without the introduction or elimination of air and without puncturing or rupturing of a membrane, diaphragm or other material. The kit concept improves the speed of the procedure, sterility, accuracy of dosing, and immediate availability of disparate items to implement the procedure in a variety of medical practice settings.

A delivery system for dispensing sterile liquids into the oral cavity using a novel pre-angled needle guidance assembly attached to a conventional anesthetic needle and conventional anesthetic syringe loaded with a novel cartridge ampule containing a certain liquid solution. This system substantially improves the efficiency of delivering small amounts of sterile fluid to the oral cavity by hypodermic means or by irrigation means using pre-angled needle guidance assemblies to temporarily bend needles or cannulas in order to reach otherwise impossible-to-reach locations within the oral cavity while also providing the ability to dispose of used needles without re-bending and thus complying with federal OSHA, state OSHA, and state regulatory disposal regulations.

The present invention provides a skin peel composition including a plurality of keratolytic substances, such as trichloroacetic acid and salicylic, and a post inflammatory hyper pigmentation reducing substance such as retinoic acid. In addition, the skin peel composition may further include ascorbic acid (vitamin C), as well as vitamins A and E. Application of the skin peel composition may be either topically in the form of a cream or gel, and may further be injected subcutaneously into the skin to achieve deeper penetration of the composition within the skin layers of the area to be treated.

The invention discloses a method for building an animal model with hyperuricemia-combined diabetes. The method comprises the following steps: 1) feeding an target animal with fodder containing 10% (by mass) of yeast powder; subjecting the target animal to a lavage with a 4% (by mass) adenine water solution according to the following dosage of 100 milligram of adenine per day per kilogram of body weight until the blood uric acid level of the target animal starts falling; 2) halving the dosage of the adenine water solution in step 1), subjecting the target animal to a subcutaneous injection with an oteracil potassium emulsion twice a day according to the following dosage of 100 milligram of oteracil potassium emulsion per day per kilogram of body weight until the target animal shows clinical symptoms of diabetes, and then obtaining the animal model with the hyperuricemia-combined diabetes. The method builds the animal model with the hyperuricemia-combined diabetes for the first time, the animal model has typical disease symptoms, the quantity index has statistical significance, and studies such as glucose clamp test and immunohistochemistry also prove that the modeling is successful. Therefore, the method for building the animal model with the hyperuricemia-combined diabetes is a reliable and practical technique.